Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489289 | 1.00 | GABRA1 (0.31) | GABRA1SIGMAR1 | |
| SCHEMBL18502978 | 1.00 | GABRA1 (0.31) | GABRA1SIGMAR1 | |
| SCHEMBL18302286 | 0.78 | KDM1A (0.36) | — | |
| SCHEMBL18502975 | 0.78 | KDM1A (0.36) | — | |
| SCHEMBL18302288 | 0.78 | KDM1A (0.36) | — | |
| SCHEMBL15897828 | 0.76 | KDM1A (0.35) | — | |
| SCHEMBL20528689 | 0.76 | GAA (0.36) | GABRA1SIGMAR1 | |
| SCHEMBL20528690 | 0.76 | GAA (0.36) | GABRA1SIGMAR1 | |
| SCHEMBL20148144 | 0.75 | POLB (0.31) | — | |
| SCHEMBL20136494 | 0.75 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428062-B2 | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-10-01 | — | — | US | disclosed |
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | AXOVANT SCIENCES GMBH (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | AXOVANT SCIENCES GMBH (CH) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044155-A1 | Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA6 | GABRA1 81/4885SIGMAR1 1869/4885 |
| US-10370370-B2 | Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | GABRA1 27/4885SIGMAR1 1704/4885 |
| US-10428062-B2 | Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | GABRA1 93/4885SIGMAR1 1881/4885 |
| US-20180134696-A1 | Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | GABRA1 25/4885SIGMAR1 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.